VEGFA and cancer: Thus, drugs targeting VEGF signaling to inhibit angiogenesis have resulted in positive outcomes in certain cancers which include VEGF-A neutralizing antibody bevacizumab, ramucirumab, and small molecule inhibitors such as sorafenib, sunitinib, pazopanib, vandetanib, axitinib, regorafenib, cabozantinib, nintedanib, lenvatinib, and apatinib (Figure 21) [30,86,89,90].